Inducing EphA3 overexpression reduced the phosphorylation of components of the phosphoinositide 3-kinase (PI3K)/BMX/signal transducer and activator of transcription 3 (STAT3) signalling pathway, increased apoptosis and decreased chemoresistance, suggesting that EphA3 has a tumour suppressor role and could be a novel therapeutic target for SCLC [26]. Here, EPHA3 is linked to neoplasm.